Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter
R3i Slides
<
Download this slidekit...
Slidekits
SSPARMα at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
SECOND EDITION
SSPARM downloadable slidekit
Originally created by Professor Jean-Charles Fruchart, President of the R3i Foundation and an internationally recognised leader in the field of PPARα research, this free-to-down slide library has been updated. The slides now include the latest information on the role of triglyceride-rich lipoproteins and their remnants in residual vascular risk, as well as the REDUCE-IT and STRENGTH cardiovascular outcomes studies.

The slide library comprises 276 slides covering:
• Atherosclerosis, metabolic syndrome, Type 2 diabetes (T2D) and associated macro- and microvascular diseases, specifically focussing on the effects of dyslipidaemia and inflammation.
• Background to triglyceride-rich lipoproteins and their remnants in residual vascular risk
• What’s new in clinical outcomes studies of triglyceride-lowering therapies.

A key focus of the slide library is the concept of selective PPARα modulation (SPPARMα), which aims to improve efficacy and minimise safety issues such as elevation in serum creatinine evident with current PPARα agonists (fibrates). The novel SPPARMα agonist pemafibrate is currently being evaluated in the PROMINENT cardiovascular outcomes study. This landmark trial will test whether treatment with this SPPARMα agonist, against a background of best evidence-based therapy including statins, reduces cardiovascular events in high risk patients with atherogenic dyslipidemia, the combination of elevated triglycerides and low HDL-C. This is the final critical test of the SPPARMα concept.

Pemafibrate is discussed in a separate slide library
Read the slidekit booklet...
PCSK9 Slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
Authors review unmet needs in the treatment of dyslipidemia, the discovery and structure of PCSK9,PCSK9 levels in health and disease, PCSK9-drug interactions focusing on statin trials, current approaches to PCSK9 inhibition, and recent results from anti-PCSK9 mAb pre-clinical and clinical trials.
 
R3i Educational Slidekit
Landmark Studies
Other Studies
DREAM Slidekits